In a presentation at the ASCO Annual Meeting, Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]
Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]
It is important that survivors keep up on the professional standards of our doctors to make sure that we receive the best care and the most current care. It is easy for doctors to just do it the way they were first trained, even if their training was twentyor thirty years ago. Recent news includes [...]
Now that we have new treatments available to fight advanced, metastatic prostate cancer we need ways to decide on the best treatments given that many of the treatments occupy the same disease space. This is especially important with the soaring costs of many treatments as well as the need to not waste time by giving [...]
The novel radiopharmaceutical radium-223 (Xofigo) appears to have long term safety with minimal adverse events. In an updated report, given at ASCO GU, on the ALSYMPCA trial of radium-233 (Xofigo), the researchers have found that there is no major safety issues identified within ~1.5 years after the completion of treatment in a population of men [...]